.

Make Better Decisions

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Johnson and Johnson
Fuji
UBS
Farmers Insurance
Daiichi Sankyo
Argus Health
Federal Trade Commission
Healthtrust
Accenture
US Department of Justice

Generated: September 21, 2017

DrugPatentWatch Database Preview

SOLODYN Drug Profile

« Back to Dashboard

What is the patent landscape for Solodyn, and what generic Solodyn alternatives are available?

Solodyn is a drug marketed by Medicis and is included in one NDA. There are nine patents protecting this drug and four Paragraph IV challenges.

This drug has thirteen patent family members in ten countries.

The generic ingredient in SOLODYN is minocycline hydrochloride. There are thirteen drug master file entries for this compound. Forty-nine suppliers are listed for this compound. Additional details are available on the minocycline hydrochloride profile page.

Summary for Tradename: SOLODYN

Patents:9
Applicants:1
NDAs:1
Suppliers / Packagers: see list2
Bulk Api Vendors: see list74
Clinical Trials: see list15
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:SOLODYN at DailyMed

Pharmacology for Tradename: SOLODYN

Ingredient-typeTetracyclines
Drug ClassTetracycline-class Drug
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Medicis
SOLODYN
minocycline hydrochloride
TABLET, EXTENDED RELEASE;ORAL050808-005Jul 23, 2009RXYesYes► Subscribe► Subscribe ► Subscribe
Medicis
SOLODYN
minocycline hydrochloride
TABLET, EXTENDED RELEASE;ORAL050808-006Aug 27, 2010ABRXYesNo► Subscribe► Subscribe ► Subscribe
Medicis
SOLODYN
minocycline hydrochloride
TABLET, EXTENDED RELEASE;ORAL050808-003May 8, 2006DISCNYesNo► Subscribe► Subscribe ► Subscribe
Medicis
SOLODYN
minocycline hydrochloride
TABLET, EXTENDED RELEASE;ORAL050808-002May 8, 2006DISCNYesNo► Subscribe► Subscribe ► Subscribe
Medicis
SOLODYN
minocycline hydrochloride
TABLET, EXTENDED RELEASE;ORAL050808-006Aug 27, 2010ABRXYesNo► Subscribe► Subscribe ► Subscribe
Medicis
SOLODYN
minocycline hydrochloride
TABLET, EXTENDED RELEASE;ORAL050808-002May 8, 2006DISCNYesNo► Subscribe► Subscribe ► Subscribe
Medicis
SOLODYN
minocycline hydrochloride
TABLET, EXTENDED RELEASE;ORAL050808-001May 8, 2006DISCNYesNo► Subscribe► Subscribe ► Subscribe
Medicis
SOLODYN
minocycline hydrochloride
TABLET, EXTENDED RELEASE;ORAL050808-007Aug 27, 2010ABRXYesNo► Subscribe► Subscribe ► Subscribe
Medicis
SOLODYN
minocycline hydrochloride
TABLET, EXTENDED RELEASE;ORAL050808-002May 8, 2006DISCNYesNo► Subscribe► SubscribeY ► Subscribe
Medicis
SOLODYN
minocycline hydrochloride
TABLET, EXTENDED RELEASE;ORAL050808-005Jul 23, 2009RXYesYes► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: SOLODYN

Drugname Dosage Strength RLD Submissiondate
minocycline hydrochlorideExtended-release Tablet55 mg and 80 mgSolodyn12/2/2010
minocycline hydrochlorideExtended-release Tablet105 rngSolodyn12/28/2010
minocycline hydrochlorideExtended-release Tablets65 mg and 115 mgSolodyn11/19/2009
minocycline hydrochlorideExtended-release Tablet45 mg, 90 mg and 135 mgSolodynPIV received prior to 2/5/2009

International Patent Family for Tradename: SOLODYN

Country Document Number Estimated Expiration
World Intellectual Property Organization (WIPO)2010017310► Subscribe
World Intellectual Property Organization (WIPO)2007001961► Subscribe
Japan5744976► Subscribe
Japan2008543936► Subscribe
Japan2013213047► Subscribe
China101208097► Subscribe
Israel188331► Subscribe
European Patent Office1898925► Subscribe
New Zealand564093► Subscribe
Norway20080444► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Colorcon
US Department of Justice
Johnson and Johnson
Cantor Fitzgerald
Healthtrust
Moodys
McKesson
UBS
Cipla
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot